MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience by C. Francisco Espinel, Shaughn Keating, Hanina Hibshoosh, Bret Taback, Kathie-Ann Joseph, Mahmoud El-Tamer, Sheldon Feldman

“…TargetPrint (TP) is an assay for assessing estrogen, progesterone, and HER2-neu receptor status based on mRNA expression. …”
Get full text

Radiological images of an advanced invasive carcinoma with mucinous aspects: A case report by Chiara Adriana Pistolese, MD, PhD, Francesca Di Giuliano, MD, PhD, Martina Cerocchi, MD, Maria Volpe, MD, Martina Cerasi Dellanea, MD, Flavia Briganti, MD, Paola Elda Gigliotti, MD, Carolina Goffredo, MD, Lucia Giudice, MD, Diletta Caccia, MD, Francesca Servadei, MD, Adriano De Majo, MD, PhD, Marco Materazzo, MD, Giorgio Pistilli, MD, Gianluca Vanni, MD, PhD, Valeria Liberto, MD

“…Immunohistochemistry study demonstrated ER positivity (95%), PR low (5%), HER-2-Neu negativity (score 0) and proliferative index (Ki67) of 20%, determining a Luminal B-like (HER 2-negative) subtype. …”
Get full text

Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]) by A. DeMichele, A. C. Dueck, D. Hlauschek, M. Martin, H. Burstein, G. Pfeiler, N. Zdenkowski, A. Wolff, M. Bellet-Ezquerra, E. Winer, M. Balic, K. Miller, M. Colleoni, D. Lake, G. Rubovsky, D. Cameron, J. Balko, C. F. Singer, Z. Nowecki, H. Iwata, N. Wolmark, K. A. Parraga, H. Rugo, G. G. Steger, T. Traina, G. Werutsky, D. Czajkowska, O. Metzger, S. El-Abed, K. P. Theall, R. D. Lu, P. O’Brien, C. Fesl, E. Mayer, M. Gnant

“…Patients diagnosed with stage II–III, hormone-receptor-positive, HER2/neu negative breast cancer within 12 months of diagnosis had completed all definitive therapy aside from endocrine therapy (started within 6 months prior to study entry) were eligible. …”
Get full text